Skip NavigationSkip to Content
Return Return to Search Results

Postexposure Prevention of Progressive Vaccinia in SCID Mice Treated with Vaccinia Immune Globulin

  1. Author:
    Fisher, R. W.
    Reed, J. L.
    Snoy, P. J.
    Mikolajczyk, M. G.
    Bray, M.
    Scott, D. E.
    Kennedy, M. C.

  2. Author Address

    [Fisher, R. W.; Reed, J. L.; Mikolajczyk, M. G.; Scott, D. E.; Kennedy, M. C.] US FDA, Lab Plasma Derivat, Div Hematol, Off Blood Res & Review,Ctr Biol Evaluat & Res, Rockville, MD 20852 USA. [Snoy, P. J.] US FDA, Div Vet Serv, Off Management, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA. [Bray, M.] NIAID, Integrated Res Facil, NIH, Ft Detrick, MD USA.;Fisher, RW, US FDA, Lab Plasma Derivat, Div Hematol, Off Blood Res & Review,Ctr Biol Evaluat & Res, HFM-345,1401 Rockville Pike, Rockville, MD 20852 USA.;Robert.Fisher@fda.hhs.gov
    1. Year: 2011
    2. Date: Jan
  2. Journal: Clinical and Vaccine Immunology
    1. 18
    2. 1
    3. Pages: 67-74
  4. Type of Article: Article
  5. ISSN: 1556-6811
  1. Abstract:

    A recently reported case of progressive vaccinia (PV) in an immunocompromised patient has refocused attention on this condition. Uniformly fatal prior to the licensure of vaccinia immune globulin (VIG) in 1978, PV was still fatal in about half of VIG-treated patients overall, with a greater mortality rate in infants and children. Additional therapies would be needed in the setting of a smallpox bioterror event, since mass vaccination following any variola virus release would inevitably result in exposure of immunocompromised people through vaccination or contact with vaccinees. Well-characterized animal models of disease can support the licensure of new products when human studies are not ethical or feasible, as in the case of PV. We chose vaccinia virus-scarified SCID mice to model PV. As in immunocompromised humans, vaccinia virus-scarified SCID animals develop enlarging primary lesions with minimal or no inflammation, eventual distal virus spread, and lethal outcomes if left untreated. Postexposure treatment with VIG slowed disease progression, caused local lesion regression, and resulted in the healthy survival of most of the mice for more than 120 days. Combination treatment with VIG and topical cidofovir also resulted in long-term disease-free survival of most of the animals, even when initiated 7 days postinfection. These results support the possibility that combination treatments may be effective in humans and support using this SCID model of PV to test new antibody therapies and combination therapies and to provide further insights into the pathogenesis and treatment of PV.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1128/cvi.00280-10
  3. View record in Web of Science®
  4. WOS: 000285869400006

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel